Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
about
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsDenosumab for the treatment of osteoporosisNew antiresorptive therapies for postmenopausal osteoporosisBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabAnalysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.Osteoporosis, fractures, and diabetes.Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.New and emerging therapies for bone metastases in genitourinary cancers.Denosumab: A comprehensive review.Methyl Gallate Inhibits Osteoclast Formation and Function by Suppressing Akt and Btk-PLCγ2-Ca2+ Signaling and Prevents Lipopolysaccharide-Induced Bone Loss.Therapeutic options for low bone mineral density in HIV-infected subjects.Skeletal and extraskeletal actions of denosumab.The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.Challenges and approaches for the development of safer immunomodulatory biologics.Safety concerns with the long-term management of osteoporosis.A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.Denosumab in osteoporosis.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Utility of the trabecular bone score (TBS) in secondary osteoporosis.Denosumab: a review of its use in postmenopausal women with osteoporosis.Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial.Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.New and emerging concepts in the use of denosumab for the treatment of osteoporosis
P2860
Q26824762-F6772DB8-8CF3-468A-8845-3858E7EBFC9DQ27009275-81A8C096-EFF8-470F-8B36-E5B0BF39D01FQ27014775-5CEABBA7-83AB-4DFC-9D0A-7AD8D90CF820Q27021268-738637BC-7A50-4BF2-9579-83D3D25C2E47Q28727655-9E3FB27A-B3E0-4292-A2B0-ED102CE3F075Q33645466-BB99E123-8E9A-40CA-9929-4F7A5C596A19Q33891378-0AF6F4E8-6CE1-4B52-BB60-30F05761330DQ35689812-8D20D67A-0627-46F2-A8E3-715D94EF62C2Q36866291-3756F7FA-9D1F-4D53-9893-CA53E0ECD6D1Q37467278-0A028552-2D0C-4D98-8F03-F58FAD72A19DQ37729189-37A11B0D-838D-4D05-877A-9A83B70EB6ECQ38005045-920204FF-EE65-4725-9638-B9BA5DBF8323Q38009712-F418B6EA-1C46-43B0-A168-96A980685AB6Q38029394-6A1E9FAE-D89B-4ED7-B245-66FA537BB217Q38093772-71182249-A737-4BBF-B2E2-9203CF8BFB73Q38101363-4522C933-02BB-4BFB-94BB-D1731C69B160Q38138862-B7E5ADF5-3B27-4C4C-9A9E-AEB18D0C4DC6Q38167352-81AFCEE1-FD28-473E-A3DB-152375F1BA69Q38193181-A553816A-C67C-442D-A29D-251934A50505Q38213973-351B090F-7B04-4BFC-812B-961E485D8E4AQ38220743-398C4CBA-46C4-44B4-BE9A-50D1D0F83BC2Q38339579-CF60E907-A614-4EC5-9D27-DC14F8448442Q38611601-054718DF-8042-4463-9D03-8D53A1CB473BQ38712724-8A9A82C4-0EB3-43C4-BF92-FA3046F693C2Q40853318-1D1269AB-2968-4FAA-ABC3-EA097CDF70A3Q41362251-459A40B1-C2C0-4130-915A-D73DCEBB162AQ47400369-CF57EEB9-9908-4C8F-BBBB-4563B50EA6C2Q58583955-2DDE1D62-BB39-41E5-8018-D4370A7C7F10
P2860
Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Infections in postmenopausal w ...... cidence or causal association?
@ast
Infections in postmenopausal w ...... cidence or causal association?
@en
type
label
Infections in postmenopausal w ...... cidence or causal association?
@ast
Infections in postmenopausal w ...... cidence or causal association?
@en
prefLabel
Infections in postmenopausal w ...... cidence or causal association?
@ast
Infections in postmenopausal w ...... cidence or causal association?
@en
P2093
P2860
P1476
Infections in postmenopausal w ...... cidence or causal association?
@en
P2093
J F Modlin
P2860
P2888
P304
P356
10.1007/S00198-011-1755-2
P407
P577
2011-09-03T00:00:00Z